FDA Inspection 1222019 — Biocore9 Llc

Biocore9 Llc — FEI 3020162561

The FDA completed an inspection of Biocore9 Llc on Nov 6, 2023 in Denville, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 12 citations were issued during this inspection. Product area: Devices.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Nov 6, 2023
Fiscal Year
2024
Product Type
Devices
Project Area
Compliance: Devices
Location
Denville, NJ (United States)

Citations

IDCFRDescription
243021 CFR 820.30(b)Design plans - Lack of or inadequate
255721 CFR 820.30(c)Design input - documentation
310421 CFR 820.30(j)Design history file
328221 CFR 820.90(a)Nonconforming product, Lack of or inadequate procedures
341521 CFR 820.22Quality Audit/Reaudit - conducted
366921 CFR 820.20(c)Management review - defined interval, sufficient frequency
367421 CFR 820.30(d)Design output - documentation
367821 CFR 820.30(g)Design Validation - Risk analysis not performed/inadequate
407021 CFR 820.30(g)Design validation - documentation
47921 CFR 820.50Purchasing controls, Lack of or inadequate procedures
54621 CFR 820.75(a)Lack of or inadequate process validation
63321 CFR 803.17(a)(3)Lack of System for Timely Submission of Reports

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.